BX Swiss TOP 30 CHF
1.185,32
PKT
-2,74
PKT
-0,23
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 03.10.22 | Richemont Buy | UBS AG | |
| 30.09.22 | Givaudan Sell | Goldman Sachs Group Inc. | |
| 30.09.22 | Richemont Overweight | JP Morgan Chase & Co. | |
| 29.09.22 | Roche Neutral | UBS AG | |
| 29.09.22 | Roche Hold | Deutsche Bank AG | |
| 29.09.22 | Roche Overweight | Barclays Capital | |
| 29.09.22 | Givaudan Sell | Goldman Sachs Group Inc. | |
| 28.09.22 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 28.09.22 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
| 28.09.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 28.09.22 | Givaudan Sell | UBS AG | |
| 28.09.22 | Givaudan Hold | Deutsche Bank AG | |
| 28.09.22 | Roche Hold | Deutsche Bank AG | |
| 28.09.22 | Swiss Re Outperform | Credit Suisse Group | |
| 27.09.22 | Richemont Market-Perform | Bernstein Research | |
| 27.09.22 | Zurich Insurance Overweight | JP Morgan Chase & Co. | |
| 26.09.22 | Novartis Neutral | UBS AG | |
| 26.09.22 | Nestlé Underperform | Jefferies & Company Inc. | |
| 23.09.22 | Novartis Sell | Deutsche Bank AG | |
| 23.09.22 | UBS Neutral | UBS AG | |
| 23.09.22 | Novartis Underweight | Barclays Capital | |
| 23.09.22 | Novartis Underperform | Credit Suisse Group | |
| 23.09.22 | Richemont Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.09.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 22.09.22 | Nestlé Buy | Goldman Sachs Group Inc. | |
| 22.09.22 | Nestlé Neutral | Credit Suisse Group | |
| 22.09.22 | ABB (Asea Brown Boveri) Buy | UBS AG | |
| 21.09.22 | Nestlé Overweight | JP Morgan Chase & Co. | |
| 21.09.22 | Givaudan Neutral | JP Morgan Chase & Co. | |
| 21.09.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 21.09.22 | Roche Hold | Deutsche Bank AG | |
| 21.09.22 | Novartis Sell | Deutsche Bank AG | |
| 21.09.22 | UBS Sector Perform | RBC Capital Markets | |
| 20.09.22 | Richemont Overweight | JP Morgan Chase & Co. | |
| 16.09.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 15.09.22 | Swiss Re Sell | UBS AG | |
| 15.09.22 | Novartis Underperform | Credit Suisse Group | |
| 15.09.22 | Roche Outperform | Credit Suisse Group | |
| 15.09.22 | Givaudan Underperform | Bernstein Research | |
| 15.09.22 | Nestlé Overweight | JP Morgan Chase & Co. |